Kalamazoo, Michigan (ots / PRNewswire) – Stryker Corporation’s Trevo® ProVue Retriever was awarded the Prix Galien USA 2014 Award for the best medical technology. The Trevo Retriever ProVue is designed to restore blood flow to the neurovaskulärem system by removing blood clots in patients with ischemic stroke. The Trevo Retriever ProVue is the first and only Stentriever® device that is fully visible at fluoroscopy. It sets a new standard in the precise positioning, visualization of the interaction between blood clots / device as well as in the removal of blood clots. This increased visibility provides physicians with real-time information that was not previously available.
As part of its ongoing mission to recognize the technical, scientific and clinical research skills that are necessary to develop innovative medicines, has the committee of Prix Galien USA in frame its eighth annual Prix Galien Awards Gala honored on October 28 excellent scientific innovations that improve the state of human health. The gala took place at the American Museum of Natural History in New York City.
“We are delighted to be recognized by the Galien Foundation and honored to such a select group of recipients of this year’s prize to belong, “said Mark Paul, president, Global Neurovascular Division, Stryker. “We strive to introduce innovative medical technologies that help us to improve the results for the patients. The Trevo ProVue Retriever is a truly innovative medical device and it opened a new era in the treatment of ischemic stroke and the removal of intrakaniellen blood clots . “
In the United States there are 795,000 strokes annually. Of which occur approximately 35 to 40% of ischemic strokes in “large vessels”, which means that the cause is a blood clot in one of the large arteries in the brain. If these are not treated, the outlook for patients is very poor. The mortality rate is 86%. The first used medical treatment for ischemic stroke is a blood-thinning agent (IV tPA) that is awarded intravenously. Studies have shown that IV tPA has only a success rate of 6-44% for the solution of blood clots in an intracranial occlusion of large vessels. In patients who are not allowed to receive IV tPA or tPA in which IV has no effect, the Trevo ProVue Retriever provides a minimally invasive surgical option for the removal of blood clots. As part of the major study TREVO 2, a forward-looking, randomized study, a revascularization of up to 92% was found. A high revascularization and ease of use have led to rapid acceptance of the Trevo Retriever ProVue. With extended use by doctors hospitals worldwide can offer this medical treatment for ischemic stroke.
The Trevo Retriever ProVue received 510 (k) marketing clearance from the US Food and Drug Administration in October 2012 Design.
Information about Galien Foundation
The Galien Foundation supports, recognizes and honors outstanding scientific innovations to improve the state of human health. The vision of the Foundation is to be a catalyst in the development of innovative treatment methods and next generation technologies, the impact on human health and save lives. The Foundation oversees and directs the activities of the Prix Galien in the USA, an international prize, the outstanding achievements in improving the human condition through the development of innovative therapies recognizes. The Prix Galien was created in 1970 in honor of Galen, the father of medical science and the modern pharmacology. Worldwide, the Prix Galien
is considered to be equivalent of the Nobel Prize in biopharmaceutical research. For more information, please visit www.galienfoundation.org [http://www.galienfoundation.org/].
information about Stryker
Stryker is one of the world’s leading medical technology companies. Together with our customers, our goal is to provide better health care. The company offers a wide range of innovative medical technologies, including reconstructive, medical, surgical and neuro-technology products as well as products for the spine, which enable people to lead more active and more satisfying life. The products and services of Stryker are available worldwide in over 100 countries. For more information contact us on www.stryker.com
For media inquiries please contact:. Yin Becker, Stryker Corporation, + 1-201-831-5000 or email@example.com [mailto : firstname.lastname@example.org]
For business inquiries please contact:. Mark Paul, Head of Stryker Neurovascular, + 1-501-413-2100 or email@example.com [mailto: mark firstname.lastname@example.org]
Web site: http://www.stryker.com/
OTS: Stryker newsroom: http://www.presseportal.de/pm/ 104169 newsroom via RSS: http://www.presseportal.de/rss/pm_104169.rss2